<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04732260</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180592</org_study_id>
    <secondary_id>2020-002924-35</secondary_id>
    <nct_id>NCT04732260</nct_id>
  </id_info>
  <brief_title>Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - STEP 1 (CYMEVAL3-STEP1)</brief_title>
  <acronym>CYMEVAL3-STEP1</acronym>
  <official_title>Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - STEP 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the model of the perfused cotyledon, Letermovir crosses the placenta to reach appropriate&#xD;
      fetal concentration. The cotyledon model can only be performed in the third trimester&#xD;
      placenta. Although it is probable that the transplacental passage in the second trimester is&#xD;
      in the same range than the one found in the 2th trimester, it needs to be confirmed. The&#xD;
      study will be divided in 2 steps: step 1 will study the Letermovir transplacental transfer in&#xD;
      the second trimester and step 2 will test the efficacy of letermovir to inhibit replication&#xD;
      in infected fetuses.&#xD;
&#xD;
      Main objective To measure the Letermovir transplacental transfer in the second trimester and&#xD;
      its accumulation in the amniotic fluid and the placenta in the second trimester&#xD;
&#xD;
      Primary end point:&#xD;
&#xD;
      Concentrations reached in fetal blood relative to EC50 of letermovir.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The eligible population of step 1 will be pregnant women in their second trimester of&#xD;
      pregnancy and undergoing TOP for any fetal abnormality and no evidence of placental&#xD;
      dysfunction.&#xD;
&#xD;
      Letermovir (LTM) is a new anti CMV drug, manufactured by Merck that:&#xD;
&#xD;
        -  is highly efficient in vitro against CMV (more than ganciclovir the gold standard drug)&#xD;
&#xD;
        -  is as efficient as valganciclovir to cure CMV infection and highly efficient as a&#xD;
           prophylaxis to avoid CMV infection and disease in bone marrow transplated patients&#xD;
&#xD;
        -  is very well tolerated&#xD;
&#xD;
        -  has no data from the use in pregnant women and animal studies are insufficient with&#xD;
           respect to fetotoxicity, but no specific concern in pregnant women arises from its&#xD;
           safety profile&#xD;
&#xD;
        -  crosses the placenta in the ex vivo model of the human perfused cotyledon to reach&#xD;
           efficient fetal concentration&#xD;
&#xD;
      In this STEP 1 study, we elected to test 2 Letermovir dosages:&#xD;
&#xD;
        -  240 mg given orally once a day. Based on 10% rate of letermovir transplacental passage&#xD;
           as demonstrated in the cotyledonon model, we calculated that the dosage of 240 mg given&#xD;
           once a day to the pregnant woman should be suffisent to reach efficient concentration in&#xD;
           fetal blood.&#xD;
&#xD;
        -  480 mg /day given orally once a day. 480 mg per day is the recommended dose to prevent&#xD;
           CMV infection in bone marrow transplanted patients;&#xD;
&#xD;
      The risks added by the study are those of letermovir: nausea, diarrhea and vomiting&#xD;
      (frequent), hypersensitivity, loss of appetite, headache, vertigo, abdominal pain, ALT and&#xD;
      AST increase, muscule spasm, blood creatinine increase, fatigue, peripheral edema (very&#xD;
      rare). The expected benefit for the women is: none.&#xD;
&#xD;
      Women and obstetrician investigator will sign the written consent for the trial.&#xD;
&#xD;
        -  Validation of inclusion and non-inclusion criteria will be assessed by the obstetrician&#xD;
           investigator as follows:&#xD;
&#xD;
        -  age, weight, height and medical history will be collected.&#xD;
&#xD;
        -  Inquiry on maternal concomitant treatment(s)&#xD;
&#xD;
        -  Blood sampling: (4 ml altogether)&#xD;
&#xD;
        -  1 Heparinate Lithium tube (2 ml) for measurements of urea, creatinine, creatinine&#xD;
           clearance, liver enzyme (ALAT ASAT GGT PAL), bilirubine&#xD;
&#xD;
        -  1 EDTA tube of 2 ml for full blood test count These measurements will be done in the&#xD;
           biochemistry laboratory of the investigating site.&#xD;
&#xD;
      When validation of inclusion and non-inclusion criteria is done (all the criteria will be&#xD;
      available on the day of the baseline visit), the woman receives the tablets of letermovir.&#xD;
      They will be allocated either 240 mg or 480 mg up until termination of pregnancy. 5 women&#xD;
      will receive 240 mg. In order to have variation in the time elapsed between administration&#xD;
      and sampling, it will be asked to 3 women to take the drug every morning and to 2 patients to&#xD;
      take the drug every evening. 5 women will receive 480 mg. This time, it will be asked to 2&#xD;
      women to take the drug every morning and to 3 patients to take the drug every evening.&#xD;
&#xD;
      Hence, the day of TOP, patients who take the drug every evening will have the largest delay&#xD;
      between the last intake and blood sampling. The patients who take the drug every morning&#xD;
      should take the last tablet early in the morning the day of TOP and latest 4 hours before the&#xD;
      blood sampling.&#xD;
&#xD;
      After the baseline visit, there will be one other visit just before TOP; the obstetrician&#xD;
      investigator will be in charge of this visit:&#xD;
&#xD;
        1. Maternal examination will comprise:&#xD;
&#xD;
             -  Inquiry of potential side effects (nausea, vomiting, diarrhea, rash, cough,&#xD;
                peripheral edema, headache, abdominal pain, decrease appetite, others)&#xD;
&#xD;
             -  SAE/AE will be collected&#xD;
&#xD;
             -  Blood pressure measurement&#xD;
&#xD;
             -  Blood sampling: (5 ml) with: one Lithium Heparinate tube for letermovir dosage&#xD;
&#xD;
             -  1 Heparinate Lithium tube (2 ml) for measurements of urea, creatinine, creatinine&#xD;
                clearance, liver enzyme (ALAT ASAT GGT PAL), bilirubine&#xD;
&#xD;
             -  Hours of the 3 intakes of pills will be recorded in an individual treatment booklet&#xD;
&#xD;
        2. At TOP, fetal examination will comprise:&#xD;
&#xD;
             -  Fetal blood sampling (5 ml in a Lithium Heparinate tube for Letermovir dosage)&#xD;
                collected at the time of feticide before lethal injection is given in the umbilical&#xD;
                vein under ultrasound guidance.&#xD;
&#xD;
             -  Amniotic fluid sampling (5 ml on Lithium heparinate tube for Letermovir dosage)&#xD;
                collected by the midwife at the time of artificial rupture of the amniotic&#xD;
                membranes.&#xD;
&#xD;
             -  Placental biopsies sampling (2 cotyledons for Letermovir dosage) collected after&#xD;
                delivery.&#xD;
&#xD;
             -  SAE/AE will be collected&#xD;
&#xD;
        3. At day 4 after TOP:&#xD;
&#xD;
      Phone call to collect SAE/AE after TOP&#xD;
&#xD;
      The duration of participation of each woman including data collection will be a maximum of 7&#xD;
      days (3 days before the TOP and 4 days after TOP).&#xD;
&#xD;
      The duration of the study will be 9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2021</start_date>
  <completion_date type="Anticipated">February 2028</completion_date>
  <primary_completion_date type="Anticipated">February 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations reached in fetal blood relative to EC50 of letermovir.</measure>
    <time_frame>At termination of pregnancy, on average 3 days after inclusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pregnant Women Undergoing TOP</condition>
  <condition>TOP - Failed Attempted Termination of Pregnancy</condition>
  <arm_group>
    <arm_group_label>letermovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maternal administration of 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letermovir</intervention_name>
    <description>Each patient will receive 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP.&#xD;
5 women will receive 240 mg. 5 women will receive 480 mg.</description>
    <arm_group_label>letermovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman ≥ 18 years old&#xD;
&#xD;
          -  in her second trimester of pregnancy&#xD;
&#xD;
          -  undergoing TOP for any fetal abnormality&#xD;
&#xD;
          -  no evidence of placental dysfunction.&#xD;
&#xD;
          -  - affiliation to a social security regime//health insurance&#xD;
&#xD;
          -  given consent for the study.&#xD;
&#xD;
          -  patient must be able and willing to comply with study visits and procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation to another interventional drug trial (category 1)&#xD;
&#xD;
          -  Subject protected by law under guardianship or curatorship&#xD;
&#xD;
          -  Woman with creatinine clearance &lt;75 ml/mn/1.73m2&#xD;
&#xD;
          -  Woman with liver insufficiency (Child Pugh grade C), AST, ALT 5 x ULN, bilirubin 2 x&#xD;
             ULN.&#xD;
&#xD;
          -  Woman with known allergy to Letermovir&#xD;
&#xD;
          -  Contraindication for the administration of Letermovir listed in the SmPC of Prevymis®&#xD;
&#xD;
          -  Woman treated by pimozide, ergot alkaloids, dabigatran, atorvastatin, simvastatin,&#xD;
             rosuvastatin, pitavastatine or cyclosporine.&#xD;
&#xD;
          -  Concomitant administration of millepertuis&#xD;
&#xD;
          -  Woman with hereditary intolerance to galactose, with lactose lapp deficiency, glucose&#xD;
             or galactose malabsorption syndrome&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne LERUEZ-VILLE, PhD &amp; MD</last_name>
    <role>Study Chair</role>
    <affiliation>Virology laboratory- reference national Lab for CMV infection -Hôpital Necker-Enfants malades, Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yves VILLE, PhD &amp; MD</last_name>
    <phone>01 71 19 63 32</phone>
    <email>ville.yves@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nelly BRIAND, PhD</last_name>
    <phone>01 44 38 18 62</phone>
    <email>nelly.briand@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker - Enfants malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Bussières, PhD</last_name>
      <phone>06 62 08 19 58</phone>
      <email>laurence.bussieres@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Faure Bardon V, Peytavin G, Lê MP, Guilleminot T, Elefant E, Stirnemann J, Leruez-Ville M, Ville Y. Placental transfer of Letermovir &amp; Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection. PLoS One. 2020 Apr 30;15(4):e0232140. doi: 10.1371/journal.pone.0232140. eCollection 2020.</citation>
    <PMID>32353010</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 24, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytomegalovirus</keyword>
  <keyword>Pregnant women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letermovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

